Karo Bio: INTERIM REPORT JANUARY-JUNE 2014

HUDDINGE, Sweden--()--Regulatory News:

Karo Bio (STO:KARO): 

The January–June period and the second quarter 2014 in brief

  • Net sales amounted to MSEK 13.2 (16.2), whereof the second quarter amounted MSEK 6.8 (8.1)
  • Net loss for the group was MSEK 27.6 (25.3), whereof the second quarter MSEK 14.2 (14.6)
  • Loss per share was SEK 0.04 (0.04), whereof the second quarter SEK 0.02 (0.03)
  • Cash flow from operating activities was MSEK -26.3 (-24.2), whereof the second quarter MSEK -13.1 (-14.3)
  • Cash and cash equivalents and other short-term investments totaled MSEK 71.9 (33.8) at the end of the period

Significant events after the end of the reporting period

  • Karo Bio was granted MSEK 3.8 from Vinnova for the development of ERbeta cancer

Conference call / audiocast today at 9.30 a.m. CET

CEO Per Bengtsson will present the report today at 9.30 a.m. in an audiocast, held in Swedish. The audiocast and slides are available through the corporate website http://www.karobio.se/ or by telephone +468 51 999 351. Questions may be submitted over the internet or by telephone.

CEO COMMENTARY

Maintained Revenue focus

The first half of 2014 has resulted in a strengthening of Karo Bio in a number of respects. Activities in our three main projects have progressed well. The collaboration with Pfizer in the RORgamma project is in an exciting phase with a number of important tests. Continued positive development of the project may also trigger further milestone payments from Pfizer to Karo Bio.

Our position in the two ERbeta projects has also strengthened. In order to reach a deal in ERbeta MS, we have now taken measures to intensify discussions with companies that have shown interest in the project. In our other project, ERbeta cancer, we are now entering the phase in which the safety of the substance we have chosen to advance into clinical trials is documented.

In the first half of the year, we strengthened our finances through the rights issue that raised net proceeds of MSEK 77. We have created revenue through the collaboration with Pfizer and implemented cost reductions. Moreover, we have been granted a total of more than MSEK 8 in “soft money” since last fall. In addition to our current operations, we will actively seek additional business opportunities in the form of attractive late projects or products.

In summary, we face an exciting period with the potential in our current projects and that which additional business opportunities may bring.

CEO Per Bengtsson

Karo Bio AB (publ) Novum

141 57 Huddinge

Sweden

Telephone: +46 8 608 60 00

Corp.reg.nr. 556309-3359

Website: www.karobio.com

The information in this report is such that Karo Bio is required to disclose under the Swedish Securities Market Act. The information was disclosed on July 11, 2014 at 8.30 a.m. CET.

This information was brought to you by Cision http://news.cision.com

Contacts

Per Bengtsson
CEO
Telephone: +46 8 608 6020
E-mail: per.bengtsson@karobio.se
or
Henrik Palm
CFO
Telephone: +46 8 608 6076
or +46 70 540 40 14
E-mail: henrik.palm@karobio.se

Sharing

Contacts

Per Bengtsson
CEO
Telephone: +46 8 608 6020
E-mail: per.bengtsson@karobio.se
or
Henrik Palm
CFO
Telephone: +46 8 608 6076
or +46 70 540 40 14
E-mail: henrik.palm@karobio.se